A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Rose bengal sodium (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Provectus Biopharmaceuticals
- 01 Oct 2014 According to company's website, results published in the Annals of Surgical Oncology (Title- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma).
- 29 Sep 2014 Data from overall analysis and sub-group data were announced in Provectus biopharmaceuticals media release.
- 28 Sep 2014 Primary endpoint 'Objective Response Rate of Lesions' has been met, according to the 39th European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History